Guardant Health (GH) on Monday said that its Shield colorectal cancer-screening blood test has received approval from the 澳洲幸运5官方开奖结果体彩网:U.S. Food and Drug⛎ Administratio𓆏n (FDA), sending shares higher.

Shield is the first blood test that the FDA has approved as a primary screening option for colorectal cancer and the first thℱat meets Medicare coverage performance requirements, the company said. The test is for adults age 45 and older who carry an average risk. 

FDA Approval Is 'Significant Victory'

"The FDA approval of the Shield test is a significant victory for patients and an important milestone in Guardant Health’s mission to conquer cancer with data," Co-澳洲幸运5官方开奖结果体彩网:Chief Executive Officer (CEO) AmirAli Talasaz said. "Shield can help improve colorectal cancer screening rates so we can ꦬdetect more cancers at an early stage, when they are treatable🍸."

In a study, the Shield test showed 83% sensitivity in detecting colorectal cancer, including 90% specificity for adv🧜anced neoplasia, the company🃏 said.

Shares of Guardant Health gained 3% to ▨$34.00 as of 2:15 p.m. ET Monday and are up 25% this year.